Product Description
Gonadorelin is a medicine that is the same as gonadotropin-releasing hormone (GnRH) that is naturally released from the hypothalamus gland. GnRH causes the pituitary gland to release other hormones (luteinizing hormone [LH] and follicle-stimulating hormone [FSH]). LH and FSH control development in children and fertility in adults. (Sourced from: https://www.mayoclinic.org/drugs-supplements/gonadorelin-intravenous-route-injection-route/description/drg-20067426)
Mechanisms of Action: GnRH Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Bangladesh | Canada | Chile | Czech | Dominican Republic | France | Germany | Greece | Hong Kong | India | Ireland | Italy | Korea | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Slovenia | South Africa | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, Czech Republic, France, Germany, Italy, Korea, Netherlands, Russia, Spain, Switzerland, Turkey, United Kingdom, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Adenocarcinoma|Prostate Cancer
Phase 2: Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PREDICT-RT* | P3 |
Recruiting |
Adenocarcinoma|Prostate Cancer |
2033-12-31 |
|
| BOUQUET | P2 |
Active, not recruiting |
Ovarian Cancer |
2028-02-28 |
12% |
| GUIDANCE | P3 |
Recruiting |
Prostate Cancer|Adenocarcinoma |
2026-11-11 |
|
| MCC-21139 | P2 |
Active, not recruiting |
Prostate Cancer |
2027-07-15 |
12% |
| NEPC Study | P1 |
Recruiting |
Prostate Cancer |
2027-06-22 |
23% |
| RADIODOSE | P1 |
Recruiting |
Prostate Cancer |
2027-12-27 |
23% |